Table 3 Antimicrobial susceptibility patterns of STEC isolates
Antibiotic | Total (n = 174) | ESBL– (n = 103) | ESBL + (n = 71) | P-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
R No. (%) | I No. (%) | S No. (%) | R No. (%) | I No. (%) | S No. (%) | R No. (%) | I No. (%) | S No. (%) | ||
Cefotaxime | 77 (44.3) | 3 (1.7) | 94 (54.0) | 7 (6.8) | 2 (1.9) | 94 (91.3) | 70 (98.6) | 1 (1.4) | – | < 0.001 |
Ceftazidime | 49 (28.2) | 20 (11.5) | 105 (60.3) | 5 (4.9) | 3 (2.9) | 95 (92.2) | 44 (62.0) | 17 (23.9) | 10 (14.1) | < 0.001 |
Piperacillin-tazo | 1 (0.6) | 11 (6.3) | 162 (93.1) | – | 5 (4.9) | 98 (95.1) | 1 (1.4) | 6 (8.2) | 64 (90.1) | 0.298 |
Ertapenem | 1 (0.6) | – | 173 (99.4) | 1 (1.0) | – | 102 (99.0) | – | – | 71 (100) | 0.405 |
Imipenem | – | 1 (0.6) | 173 (99.4) | – | 1 (1.0) | 102 (99.0) | – | – | 71 (100) | 0.405 |
Ciprofloxacin | 44 (25.3) | 10 (5.74) | 120 (69.0) | 14 (13.6) | 4 (3.9) | 85 (82.5) | 30 (42.4) | 6 (8.2) | 35 (49.4) | < 0.001 |
Levofloxacin | 42 (24.1) | 3 (1.7) | 129 (74.2) | 10 (9.7) | 2 (1.94) | 91 (88. 4) | 32 (45.1) | 1 (1.4) | 38 (53.5) | < 0.001 |
Amikacin | 1 (0.6) | 6 (3.4) | 167 (96.0) | – | 3 (2.9) | 100 (97.1) | 1 (1.4) | 3 (4.2) | 67 (94.4) | 0.429 |
Tetracyclines | 100 (57.5) | 4 (2.3) | 70 (40.2) | 44 (42.7) | 3 (2.9) | 56 (54.4) | 56 (78.9) | 1 (1.4) | 14 (19.7) | < 0.001 |
Ampicillin | 119 (68.4) | 5 (2.9) | 50 (28.7) | 49 (47.6) | 5 (4.9) | 49 (47.6) | 70 (98.6) | – | 1 (1.4) | < 0.001 |
Trimethoprim-sulfa | 104 (59.8) | – | 70 (40.2) | 43 (41.7) | – | 60 (58.3) | 61 (85.9) | – | 10 (14.1) | < 0.001 |